author-photo

Ann J Barbier

Agios Pharmaceuticals

9

Papers

67

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Phase 1 Single‐ and Multiple‐Ascending‐Dose Randomized Studies of the Safety, Pharmacokinetics, and Pharmacodynamics of AG‐348, a First‐in‐Class Allosteric Activator of Pyruvate Kinase R, in Healthy Volunteers

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (14)
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency

2019 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (44)
Patient Voice in Rare Disease Drug Development and Endpoints

2017 Therapeutic Innovation & Regulatory Science
Show All
- Source
- Cite
- Save
Citations (2)
Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Population Pharmacokinetics and Pharmacodynamics of AG-519, a Pyruvate Kinase Activator for the Treatment of Pyruvate Kinase Deficiency, in Human Healthy Volunteers

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients

2016 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study

2016 Blood
Show All
- Source
- Cite
- Save
Citations (5)
DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency

2015 Blood
Show All
- Source
- Cite
- Save
Citations (1)